BioVenture

RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.

Shanhai Innovation is a biological development company focused on supramolecular science and technology research and development. It provides supramolecular material, organic liquid, ionic salt, and biocatalysis. It serves biomedicine, daily cosmetics, health food, medical equipment, and food additives.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.

Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Secretech is a research and development-driven biotechnology company focused on creating biomarkers and cellular exosomes. It specializes in developing a molecular detection technology platform designed to offer innovative solutions across scientific, clinical, and drug discovery sectors. The company is dedicated to advancing a new generation of molecular detection methods, integrated with advanced computational biology algorithms. This approach enables Secretech to deliver robust proteomics analysis tools that facilitate the rapid discovery of new molecular markers.

Chuanxin Biotech is an RNA drug research and development service provider.

Changsha Morning Shine is an innovative pharmaceutical company that specializes in R&D outsourcing, biomedicine, chemical drugs, and biotechnology services.

Shanghai Kechow Pharma is a biopharmaceutical company based in Shanghai that pursues novel drug discovery with a focus on oncology. It develops targeted small molecule therapies and participates in co-development with partners, covering research, clinical development, and regulatory registration. Founded in 2014, the company emphasizes creating new anti-cancer drugs to address clinical needs and strives to bring high-quality oncology treatments to patients.

Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates.

Huili Pharmaceutical is a drug delivery platform that specializes in the development of nanoparticles and microsphere preparation equipment.

Essentia Biosciences is a biotechnology company that specializes in the development of cells, gene technology drugs, and medical devices.

Gene Cradle is a genetic company that develops gene therapy drugs to treat rare genetic diseases as well as chronic diseases.

Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.

Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Ruoyi Biotech is a developer of macromolecular drug delivery technology.

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, specializing in biopharmaceutical development and manufacturing services. Established in 2013, the company offers a wide range of services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. It also supports clients with technical transfer, regulatory guidance, and project management to ensure a comprehensive solution throughout the biopharmaceutical development lifecycle. Chime Biologics focuses on delivering customer-centric, cost-effective, high-quality services that cater to the evolving needs of the biopharmaceutical industry, facilitating early-stage development through late-stage clinical research and commercial production.

Human Zhizao is a technology platform that provides comprehensive diagnostic solutions. They provide clinical customers with a parallel, full-automatic multiple flow cytometry fluorescence detection platform and supporting reagents. They provide customer service. The flow fluorescence luminescence technology is a new generation of throughput detection and analysis platform integrating flow analysis, laser analysis, digital signal processing, and other technologies. They involve projects that require the joint detection of multiple indicators, such as autoantibodies, allergens, cytokines, etc.

ProxyBio develops treatment and pharmaceutical products for mRNA development.

Hanchao Pharmaceutical is a biopharmaceutical company that specializes in the development and production of medical equipment and solutions for the biomedical industry. The company's core focus is on providing single-use bioprocessing solutions, with a particular emphasis on biomedical production technology. Hanchao independently designs, manufactures, and sells a range of equipment and consumables, catering to the industrialization stage of various biomedical fields, including antibodies, vaccines, antibody-drug conjugates (ADCs), and cell and gene therapies (CGTs).

Lealing Biotech developes anti-body based drugs and pharmaceutical products.

NeuShen Therapeutics develops therapies for neurological and psychiatric disorders by integrating small molecule discovery with AAV-based gene therapy. The company's platform combines therapeutic compounds and gene delivery systems to address central nervous system conditions through targeted mechanisms, scalable clinical development, and a dual-modality approach that supports precision medicine and broad therapeutic applicability.

Cell Probio is a manufacturer of cell culture consumables, positioned in the R&D, production and sales of high-end biological consumables.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

SiranBio is a biotechnology company specializing in the development of innovative drugs based on small interfering RNA (siRNA) technology. The company focuses on creating single-target and dual-target nucleic acid drug platforms, as well as extrahepatic delivery systems. Its pipeline includes potential treatments for a wide range of diseases, such as viral infections, cardiovascular and metabolic disorders, autoimmune conditions, and central nervous system disorders. SiranBio aims to provide reliable and innovative products to its customers.

Resproly specializes in the research, development, production, and sales of respiratory inhalation formulas and equipment. The company focuses on clinically demanding treatment areas such as asthma, COPD (Chronic Obstructive Pulmonary Disease), diabetes, and Parkinson's disease.

Biocreatech is a biotechnology firm that uses protein design and synthetic biology to create cell factories capable of producing a range of products such as drug intermediates, fine chemicals, functional peptides, and therapeutic proteins. They involve in integrating multiple proteins into molecular machines in order to transform cells into factories.

Enzymaster (Ningbo) Bio-Engineering Co., Ltd. is a biotechnology company focused on the development and commercialization of innovative enzyme catalysis technologies. Founded in 2013 and based in Ningbo, China, the company specializes in the production of custom enzymes and biocatalytic synthesis for various applications, including active pharmaceutical ingredient intermediates, fine chemicals, and consumer goods. Enzymaster's product portfolio features compounds such as L-tert-leucine, Methyl (R)-3-Hydroxybutyrate, and D-Calcium Pantothenate. The company employs advanced techniques in enzyme-directed evolution, strain engineering, and fermentation process development to promote environmentally friendly and safe manufacturing practices across industries such as pharmaceuticals, food, and environmental conservation. Enzymaster is committed to sustainable practices and aims to contribute positively to society and the environment through its carbon-neutral intelligent manufacturing processes.

Juncell Therapeutics is a biopharmaceutical company focused on developing innovative therapies for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are then cultivated outside the human body before being reintroduced to patients, aiming to enhance the body's ability to combat tumors while minimizing side effects. Through its research and development efforts, Juncell Therapeutics seeks to advance treatment options in the medical industry, ultimately improving patient outcomes in cancer therapy.

InnoBM Pharmaceuticals is a company specializing in the development of biomaterials and pharmaceutical products. It focuses on creating novel therapeutics aimed at enhancing the efficacy of tumor immunotherapy, thereby addressing critical needs in cancer treatment. By committing to innovation, InnoBM Pharmaceuticals strives to improve outcomes for cancer patients through advanced therapeutic solutions.

Yuanjingtaico is a biotech firm focused on the R&D of fluorescent PCR reagents, microfluidic, and electrochemical detection products.

KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company focuses on creating a comprehensive range of biological heart valves and annuloplasty rings that are designed to be minimally invasive. Utilizing cutting-edge technologies, including anti-calcification and leaflet thinning methods, KingstronBio aims to provide innovative solutions that enhance patient outcomes and improve the overall effectiveness of cardiac procedures.

Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs.

Beijing Changmugu Medical Technology Co., Ltd. is a healthcare start-up that specializes in developing artificial intelligence-powered solutions for medical and surgical applications. Based in Beijing, China, the company focuses on enhancing orthopedic procedures through advanced technology. It offers a range of services including AI-assisted diagnosis, individualized surgical planning, 3D printing for patient-specific instrumentation, and post-operative evaluation. By leveraging deep learning algorithms, Changmugu Medical aims to improve the precision and safety of orthopedic surgeries, ultimately providing patients with more secure and reliable treatment options.

Comma Bio is a comprehensive solution provider for sample pretreatment. Based on two types of snap-neck material technologies of adsorption and separation materials and filter materials, the company has created three major technology platforms for porous plastics, separation materials and precision injection molding. Customers in the fields of, precision medicine, analysis and testing provide comprehensive solutions for sample pre-processing.

Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Bioligo, officially known as Shanghai Bailige Biotechnology Co., Ltd., is a biotechnology company specializing in the provision of high-quality DNA synthesis and sequencing services. The company focuses on serving the genetic and molecular diagnostics sector, which is integral to the field of precision medicine. Bioligo offers a range of products, including DNA primers, fluorescently labeled probes, and RNA synthesis products. Additionally, they supply essential materials for next-generation sequencing library construction, such as adapters, blocking agents, and target capture probes. By addressing critical gaps in raw materials, Bioligo supports its downstream customers in the in vitro diagnostic industry, enhancing their capabilities in precision medicine applications.

Guangzhou Creative Biosciences, established in Guangzhou, China, specializes in the research, development, production, and sales of diagnostic kits for colorectal cancer screening. Their primary product is a non-invasive fecal DNA screening kit, which enables early detection of colorectal cancer by interpreting genetic abnormalities in feces. Additionally, the company offers diagnostic kits and equipment for lung cancer.

Boan Biotech is a biopharmaceutical company focused on developing therapeutic antibodies for oncology, metabolism, autoimmunity, and ophthalmology. It conducts development, manufacturing, and commercialization of biologics and serves customers in China and international markets, with operations based in Shandong, China.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

NeuExcell Therapeutics is an early-stage gene therapy company dedicated to addressing neurodegenerative diseases and neural injuries. The company has developed an innovative neural repair technology that facilitates the conversion of astrocytes into neurons through in vivo methods. By employing adeno-associated virus-based gene therapy to introduce neural transcription factors, NeuExcell aims to enable clinicians to restore damaged neural tissue. The company's mission is to enhance the quality of life for millions of patients worldwide who are affected by neurodegenerative conditions.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.

Synaptic Medical Inc. is a medical device company dedicated to developing and commercializing innovative products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Established in 2005 and headquartered in St. Paul, Minnesota, the company also maintains an office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology, offering a range of products including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation devices. The company's focus is on creating unique, cost-effective, and clinically advanced technologies that enhance treatment options for physicians and their patients.

Tavotek Biotherapeutics is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with significant unmet medical needs in cancers, autoimmune conditions, and infectious diseases. The company utilizes three platform technologies—TavoSelect, a phage display library; TavoPrecise, an engineering platform for tissue-specific biologics; and TavoMIP, a multicyclic peptide platform—to advance a diverse pipeline across multiple development stages. Its leadership includes veteran pharmaceutical executives and advisors with experience in bringing biologics to market.

Pro-Heal Pharmaceuticals is a biotechnology company that specializes in the development and manufacturing of pharmaceutical products. It focuses on creating drugs for ophthalmic and autoimmune diseases, addressing critical needs in the pharmaceutical field. By concentrating on biological macromolecule therapies and ophthalmology medicines, Pro-Heal aims to provide effective treatments that are currently lacking in clinical settings, thereby improving patient outcomes. The company's commitment to innovation and development positions it as a valuable player in the healthcare industry, dedicated to meeting urgent medical needs.

Beijing Changmugu Medical Technology Co., Ltd. is a healthcare start-up that specializes in developing artificial intelligence-powered solutions for medical and surgical applications. Based in Beijing, China, the company focuses on enhancing orthopedic procedures through advanced technology. It offers a range of services including AI-assisted diagnosis, individualized surgical planning, 3D printing for patient-specific instrumentation, and post-operative evaluation. By leveraging deep learning algorithms, Changmugu Medical aims to improve the precision and safety of orthopedic surgeries, ultimately providing patients with more secure and reliable treatment options.

Kyinno is a biopharmaceutical company specializing in the development of oncology drugs. Its focus lies in immune treatments against cancer and next-generation kinase inhibitor design.

VesiCURE Therapeutics is a biotechnology company based in Suzhou, Jiangsu, China, founded in 2021. It specializes in the research and development of innovative drugs utilizing exosomes, also known as extracellular vesicles. The company is dedicated to advancing the understanding and application of exosomal drugs, contributing to the growth and enhancement of the exosomal pharmaceutical industry. Through its research initiatives, VesiCURE aims to promote the development of effective therapies that harness the unique properties of exosomes for medical applications.

PegBio is a biopharmaceutical company based in Suzhou, focused on polyethylene glycol (PEG) chemistry and PEGylation technology to develop and manufacture PEGylated drugs as potential new molecule entities. The company offers PEG synthesis and PEGylation services, including N-terminal specific, thiol-selective, and enzymatic PEGylation, along with pharmaceutical-grade PEGs and activated PEGs for research and pharmaceutical applications. It provides PEGylation services to universities, research institutes, and pharmaceutical companies and develops PEGylated peptides and antibody fragments for therapeutic areas such as type II diabetes and rheumatoid arthritis. PegBio also develops PB-119, a glucagon-like peptide-1 (GLP-1) receptor agonist designed for less frequent dosing, and engages in collaborations with strategic partners to modify macromolecules and advance PEGylated biopharmaceuticals.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

Zhejiang Pushikang Biotechnology offer In-vitro diagnostics solutions.

X-ABT is a tech enterprise that provides solutions for pathogenic microorganism detection in the medical and health fields. The company focuses on providing complete solutions for the detection of infectious pathogens in the medical and health field. They develop and produce systems for disease control, prevention, clinical hospitals, and entry-exit customs. X-ABT also provides clinical marketing and sales services to help medical workers and serve patients.

Borayer is a biotechnology company that specializes in the development and production of biological materials for clinical medicine. The company focuses on creating medical consumables aimed at wound repair, including products that facilitate rapid hemostasis, wound adhesion, and guided tissue regeneration. Through its innovative offerings, Borayer aims to enhance clinical medical products and technologies, contributing to improved patient outcomes in various healthcare settings.

Shanghai Bioheart Biotechnology Co., Ltd., established in 2014 and located in Shanghai, China, specializes in the development of drug-eluting stents. The company is focused on creating innovative, high-value minimally invasive therapeutic products. Bioheart aims to enhance medical technology and provide superior healthcare solutions for medical professionals and patients alike, positioning itself as a significant player in the medical and healthcare industry.

EOC Pharma Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. It specializes in the development, manufacturing, and commercialization of innovative oncology products. EOC employs a licensing model to enhance its product pipeline by incorporating molecules from global biopharmaceutical partners into its robust local infrastructure, which includes manufacturing, clinical development, regulatory filing, and commercialization. The company has a diverse pipeline featuring seven novel products, several of which are positioned as potentially first- and best-in-class. EOC has achieved regulatory milestones with four Class I innovative drug approvals and has initiated clinical studies for its leading products. The company operates an 8,000 square meter cGMP manufacturing facility in Taizhou and maintains offices in key locations, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team of experienced professionals, EOC aims to establish itself as a leader in oncology innovation in China through strategic partnerships and a comprehensive integrated platform.

Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.

RainSure Scientific is a medical-based manufacturing company that produces PCR instruments, assays, and healthcare services.

Founded in 2015, DiaMonTech specializes in developing non-invasive medical diagnostic devices. Its proprietary photo-thermal detection technology enables accurate glucose level measurements without finger pricking or blood samples.

Antai Kangcheng is a research and development company specializing in tumor electric field treatment technology, particularly aimed at addressing glioblastoma multiforme. The company is dedicated to creating innovative treatment methods and equipment for tumor management and central nervous system injury rehabilitation. Antai Kangcheng has developed a precise treatment planning system that integrates biophysical models with multimodal imaging systems, allowing for personalized treatment solutions tailored to the needs of Chinese patients. Furthermore, the company has achieved the visualization of intracranial electric field strength and can effectively manage electro-nodes to track tumors, enabling patients to receive effective treatment at a lower cost.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

Allist Pharmaceuticals is a pharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative medicines, particularly in the field of cancer treatment. The company is driven by the unmet clinical needs within the global pharmaceutical market and is committed to advancing long life through scientific and technological innovation. Allist Pharmaceuticals aims to create safe, effective, and inclusive drugs, holding independent intellectual property rights for its products.

Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.

CART Medical Technologies is a high-tech company focused on advancing immune cell therapy through innovative technologies. The company specializes in developing CAR-T cells, which can target both protein antigens and glycolipid non-protein antigens, thereby expanding the range of tumor antigen targets. This approach enhances T-cell generation and activation, leading to more effective treatments for various diseases. CART Medical operates out of a 2,200 square meter facility that includes GMP laboratory and research and development laboratories.

Isia Biotech is a developer and producer of in vitro diagnostic (IVD) medical technology that focuses on detecting and diagnosing diseases through immune reactions. The company utilizes its proprietary quantum dot technology to enhance the accuracy of tests for various medical conditions, including cardiovascular disease, inflammation, bone metabolism, gastric function, renal function, cancer, and other autoimmune diseases. By advancing diagnostic capabilities, Isia Biotech aims to support healthcare providers in improving disease detection, diagnosis, and treatment. Their commitment to research and development, alongside the production and sales of diagnostic instruments, positions them as a significant player in the medical technology sector.

DeepCyto is a medtech company based in Suzhou, Jiangsu, China, established in 2018. The company specializes in the development of digital hematology pathology and diagnostic equipment, incorporating artificial intelligence and deep learning technologies to enhance medical diagnosis and data analysis. By leveraging machine vision and big data mining, DeepCyto offers intelligent diagnostic models that address various blood diseases, aiming to improve the accuracy and efficiency of medical assessments.

Shanton Pharma Co., Ltd. is a biotechnology research organization founded in 2016 and based in Shanghai, China. The company specializes in the research and development of innovative therapies aimed at addressing significant unmet medical needs, with a particular focus on uric acid metabolism, inflammatory pain, and gout metabolic syndrome diseases. Shanton Pharma has dedicated substantial efforts to the field of gout diseases, where it has developed a promising product, SAP-001, which has demonstrated safety and efficacy. The company aims to commercialize its core products and deliver innovative new medicines to patients and the medical community.

Innovita Biological Technology Co., Ltd., established in 2006 in Beijing, is a Chinese biotechnology company specializing in the research, development, manufacturing, marketing, and after-sales service of in-vitro diagnostic tests. In 2011, the company expanded by opening a new facility in Tangshan, Hebei province, which includes five production lines for colloidal gold, real-time PCR, chemiluminescence, ELISA, and biochips. This facility spans 250 acres and features a 4,000-square-meter purification plant, with a designed annual output of up to 20 million tests. Innovita holds ten invention patents and has received certifications such as CE, ISO 13485, and GMP. Its extensive product line includes tests for fertility, infectious diseases, sexually transmitted diseases, respiratory diseases, drug abuse, tumor markers, and cardiac markers.

Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies, specifically targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in the biotechnology sector. By providing antibody-based drugs that enhance immune system functionality, along with technical consultation and drug quality inspection services, Kanova enables its clients to improve drug quality and efficiently advance the field of biomedicine.

Ningbo Senscure Biotechnology Co., Ltd specializes in the innovation and enhancement of minimally invasive surgery technologies, focusing primarily on single incision laparoscopic surgery (SILS) and natural orifice transluminal endoscopic surgery (NOTES). The company is dedicated to tumor treatment and offers a range of surgical devices, including a laparoscopic single port multi-channel access platform, a pulmonary nodule localization needle, a tumor cryoablation system, and an anti-gastroesophageal reflux system. Senscure provides comprehensive medical equipment solutions designed to facilitate minimally invasive surgeries.

Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy.

YXgene is a Pharmaceutical company for development of virus vectors, preclinical studies and investigational new drug application

POCTech Medical develops a CGM sensor product for the diabetes care communities.

Founded in 2013, LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and rare diseases. Its pipeline includes LAM-001 for lymphangioleiomyomatosis, LAM-002 for B-cell non-Hodgkin lymphoma, and other clinical stage drugs.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

Genowise is a company specializing in advanced genetic testing and medical diagnostic services. It offers a range of services, including pharmacogenomics, auxiliary diagnosis, and tumor genome diagnosis. Genowise has developed next-generation gene sequencing reagents and a clinical data analysis system to enhance the effectiveness of genetic testing. The company provides over 15 different genetic testing kits that cover more than 170 diseases and assess over 810 known gene loci, facilitating better health management for patients. Through its innovative approach, Genowise aims to improve diagnostic accuracy and support personalized medicine initiatives.

KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company focuses on creating a comprehensive range of biological heart valves and annuloplasty rings that are designed to be minimally invasive. Utilizing cutting-edge technologies, including anti-calcification and leaflet thinning methods, KingstronBio aims to provide innovative solutions that enhance patient outcomes and improve the overall effectiveness of cardiac procedures.

IMPACT Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009 and based in Shanghai, China, the company focuses on creating targeted anti-cancer treatments utilizing synthetic lethality. IMPACT Therapeutics is actively engaged in several research and development projects, including a PARP inhibitor, a Wee1 inhibitor, and various novel agents targeting DNA damage response mechanisms and the Hedgehog signaling pathway. Through its commitment to advancing treatment options, IMPACT Therapeutics aims to provide patients with effective and targeted anti-cancer therapies.

Shanghai Kechow Pharma is a biopharmaceutical company based in Shanghai that pursues novel drug discovery with a focus on oncology. It develops targeted small molecule therapies and participates in co-development with partners, covering research, clinical development, and regulatory registration. Founded in 2014, the company emphasizes creating new anti-cancer drugs to address clinical needs and strives to bring high-quality oncology treatments to patients.

Aixing Biotechnology manufacture biopharmaceutical and IVD equipment for healthcare services.

Ascentage Pharma is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers, hepatitis B virus (HBV), and age-related diseases. Its pipeline comprises seven drug candidates targeting protein-protein interactions and tyrosine kinases.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Admera Health, LLC is a molecular diagnostics company based in South Plainfield, New Jersey, specializing in personalized medicine and non-invasive cancer testing. Founded in 2012, the company operates a laboratory that develops, validates, and delivers proprietary laboratory-developed tests. Admera Health offers a range of services, including PGxOne, a pharmacogenomics test that assesses patient responses to drug therapy based on genetic makeup, and DNA sequencing for analyzing mutations in EGFR and KRAS. Additionally, it provides tests to evaluate risks for inherited health conditions such as high cholesterol and diabetes. The company's product pipeline includes the OncoGxOne cancer panel, which identifies genomic variations related to cancer, and FloraCheck, which analyzes microbiome composition for health management. Utilizing advanced genomic technologies and bioinformatics, Admera Health aims to enhance disease screening, diagnosis, and treatment, ultimately improving health outcomes for patients and supporting healthcare providers and researchers.

Yulu Qianxing is an AI-powered platform that focuses on quantum mechanics, and molecular simulation algorithms to enable novel drug research and development by simulating processes.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.